Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CELC
Strong SellSinkerCelcuity Inc. · Healthcare · United States · $4.3B · Avg Vol: $68M/d
COMPANY DESCRIPTION
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for oncology, utilizing its proprietary CELsignia companion diagnostic platform. The platform analyzes live tumor cells from patients to identify active signaling pathways, enabling more precise patient selection for its lead drug candidate, gedatolisib. Celcuity's competitive moat is built on this integrated approach of combining functional cellular diagnostics with targeted therapeutic development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 37.1M | 370.1M | — |
| EPS | -1.17 | -2.69 | -2.83 | -3.79 | — | -4.30 | -4.39 | 0.96 | — |
| Shares | 48.8M | 25.5M | 37.1M | 48.2M | -1.1% | 48.9M | — | — | — |
| Debt | 35.2M | 37.4M | 98.0M | 321.9M | 109.0% | 754.4M | — | — | — |
| Equity | 133.8M | 139.8M | 115.6M | 100.6M | -9.1% | — | — | — | — |
| Op CF | -36.0M | -53.8M | -83.5M | -153.3M | — | -191.7M | — | — | — |
| Inv CF | -144.0M | -5.0M | -63.1M | -64.1M | — | — | — | — | — |
| Fin CF | 120.3M | 64.9M | 138.4M | 360.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CELC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CELC | Celcuity Inc.(you) | $4.3B | 10 | Strong Sell |
| DYN | Dyne Therapeutics, Inc. | $4.7B | 13 | Strong Sell |
| RCUS | Arcus Biosciences, Inc. | $3.7B | 14 | Strong Sell |
| GPCR | Structure Therapeutics Inc. | $3.4B | 13 | Strong Sell |
| TNGX | Tango Therapeutics, Inc. | $3.9B | 17 | Strong Sell |
| COGT | Cogent Biosciences, Inc. | $6.0B | 12 | Strong Sell |
| ALMS | Alumis Inc. | $2.9B | 9 | Strong Sell |
| BEAM | Beam Therapeutics Inc. | $3.0B | 13 | Strong Sell |
| PBLS | Parabilis Medicines, Inc. | $4.8B | 2 | Strong Sell |
| VKTX | Viking Therapeutics, Inc. | $3.8B | 18 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%